Sumitomo Chemical India Ltd
SUMICHEMSumitomo Chemical India Ltd is coiled. The quarters are improving, yet the P/E sits at the 21st percentile of its own 6-year range — the business is moving before the market.
The sharpest disagreement: annual EPS moved +7.4% against a −19.1% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (3 weeks in) while the P/E sits at the 21st percentile of its own 6-year range. Underneath, the last four quarters read improving — profit +20.8% year on year, and 117% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sumitomo Chemical India Ltd trades at ₹510, in a confirmed uptrend and 3 weeks into that stage. That is +8.5% against its own 200-day average. It sits at 60% of a 52-week range of ₹375 to ₹602. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks.
Today the stock is in a confirmed uptrend — week 3 of stage 2, confirmed. At ₹510 it trades +8.5% versus its 200-day average and sits at 60% of its 52-week range (₹375–₹602).
Against the market, two honest reads. Cumulative: over the last 6.5 years the stock moved +121% while the NIFTY 500 moved +136% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sumitomo Chemical India Ltd trades at 44.6× P/E, near the bottom of its own range — cheaper only 21% of the time. Its long-run median P/E is 51.7×, measured across 6.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 44.6× is near the bottom of its own range — cheaper only 21% of the time, against a long-run median of 51.7× measured over 6.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +7.4% against a −19.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +3.8%/yr price move, ~+10.9%/yr came from earnings growth and ~−7.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sumitomo Chemical India Ltd reads as consistent on its fundamental arc. Consistent — profit and EPS growth have stayed positive through the window, with ROCE at 22.7% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +2.8% | −2.7% | +4.1% | — |
| Profit | +7.3% | +2.7% | +9.5% | — |
| EPS | +7.4% | +2.6% | +9.5% | — |
| Share price | −19.1% | +7.8% | +3.8% | — |
4-Factor Sector Score
45.4/100 — rank 14 of 24 in Pesticides/Agrochemicals · 94% evidence confidence
Sumitomo Chemical India Ltd scores 45.4 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 14. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 12.1 + 19 + 4 + 10.3 = 45.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sumitomo Chemical India Ltd reported ₹1,063 Cr of revenue in the Jun 26 quarter, +0.6% year on year. That is the 2nd straight quarter of year-on-year growth. Over 8 years it has compounded at 6.8% a year. The last full year, FY26, came in at ₹3,238 Cr. The last four reported quarters add to ₹3,245 Cr.
FY26 revenue came in at ₹3,238 Cr (+2.8% on the year), capping 8 years at 6.8% compound. The latest quarter (Jun 26) printed ₹1,063 Cr, +0.6% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged −4.0% growth against the decade's 6.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −3.6% over the last 4 quarters against +4.7%/yr over the last 8 — rolling over; TTM profit +3.9% vs +15.5%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sumitomo Chemical India Ltd's operating margin is 22.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 9 fiscal years the operating margin has ranged 11.0% to 21.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 22.0%, +1.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 11.0%–21.0%, and FY26's 21.0% is the top of that band — a record year.
Why the margin moved: operating margin went +1.2 pp year on year while gross margin went +1.1 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sumitomo Chemical India Ltd earned ₹215 Cr of net profit in the Jun 26 quarter, +20.8% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹543 Cr. The 8-year compound rate is 17.9%. That is 20.2% of the quarter's revenue. The same quarter a year earlier earned ₹178 Cr.
Jun 26 profit was ₹215 Cr, +20.8% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹543 Cr (+7.3%), and the 8-year compound rate is 17.9%.
Why profit moved: revenue contributed +0.6% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +2.9% vs revenue −4.0%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 117% of Sumitomo Chemical India Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹446 Cr of operating cash against ₹543 Cr of profit. After ₹79.0 Cr of capital spending, ₹367 Cr was left as free cash.
FY26: operating cash of ₹446 Cr against reported profit of ₹543 Cr, leaving free cash of ₹367 Cr after ₹79.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 117% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 117%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sumitomo Chemical India Ltd's cash conversion cycle runs 163 days in FY26, up from 157 days in FY21. Capital spending ran ₹290 Cr over the last 3 years. At FY26 sales of ₹3,238 Cr each day of that cycle holds about ₹8.9 Cr, so roughly ₹1,446 Cr sits inside the business at any moment.
FY26: debtors at 83 days, inventory at 166 days — roughly 5.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 163 days, looser than FY21's 157.
The full loop: cash goes out to suppliers and production on day 0; stock waits 166 days to sell; customers pay about 83 days after that; and suppliers themselves are paid at 86 days — netting out to the 163-day cycle.
In money terms: at FY26 sales of ₹3,238 Cr, each day of the cycle holds about ₹8.9 Cr — so the 163-day loop keeps roughly ₹1,446 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹290 Cr over the last 3 fiscal years against ₹194 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹20.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Sumitomo Chemical India Ltd earns a ROCE of 22% in FY26. That is up from a trough of 20% in FY24. Return on invested capital clears the cost of that capital by +9.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 16.8% net margin on 0.72× asset turns.
FY26 ROCE is 22%, recovered from a FY24 trough of 20% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 16.8% net margin × 0.72× asset turns × 1.32× balance-sheet leverage ≈ 16.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 21.3% − 12.0% = a +9.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Sumitomo Chemical India Ltd carries total debt of ₹63.0 Cr against shareholder equity of ₹3,394 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.02 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹63.0 Cr against shareholder equity of ₹3,394 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.02 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 2.2 points of Sumitomo Chemical India Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 9.3% of the company. Promoters moved +0.0 points over the same window, to 75.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +2.2 points over 8 quarters to 9.3%; Promoters: +0.0 points over 8 quarters to 75.0%; Foreign institutions: +0.0 points over 8 quarters to 3.0%.
Why the register moved: domestic institutions drove it (+2.2 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sumitomo Chemical India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Titan Biotech Ltd524717 | 69.3/100Favorable setup78% evidence | ASLEEP | 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 6.9 pp 83% evidence | 20.2/25 ROCE 22.8% · OPM 19.9% 76% evidence | 6.0/20 P/E 57.8× · PEG — 50% evidence | 14.0/20 RS sector 41.7% · RS bench 39.3% · 1Y 371.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 20.2 + 6 + 14 = 69.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Sharda Cropchem LtdSHARDACROP | 65.3/100Favorable setup97% evidence | ASLEEP | 23.7/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 95% evidence | 18.5/25 ROCE 30.2% · OPM 17% 95% evidence | 19.2/20 P/E 11.8× · PEG 0.26 100% evidence | 3.9/20 RS sector -10.9% · RS bench -13.7% · 1Y -24.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 18.5 + 19.2 + 3.9 = 65.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.9% and the one-year return is -24.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Punjab Chemicals & Crop Protection LtdPUNJABCHEM | 61.8/100Mixed-positive evidence81% evidence | ASLEEP | 22.7/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 18.3/25 ROCE 18.6% · OPM 12% 95% evidence | 12.1/20 P/E 21× · PEG — 50% evidence | 8.7/20 RS sector -6.2% · RS bench -2.6% · 1Y -13.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 22.7 + 18.3 + 12.1 + 8.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Bayer CropScience LtdBAYERCROP | 61.7/100Mixed-positive evidence70% evidence | ASLEEP | 21.4/35 Revenue 3.7% · PAT 21.7% · OPM change 2.1 pp 83% evidence | 19.1/25 ROCE 20.1% · OPM 18.4% 95% evidence | 8.5/20 P/E 387× · PEG — 15% evidence | 12.7/20 RS sector 9.4% · RS bench -10.7% · 1Y -33.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.4 + 19.1 + 8.5 + 12.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Dharmaj Crop Guard LtdDHARMAJ | 61.1/100Mixed-positive evidence62% evidence | TURNING | 23.8/35 Revenue 19.6% · PAT 56.9% · OPM change 2.7 pp 62% evidence | 12.9/25 ROCE 16.4% · OPM 4.5% 95% evidence | 10.6/20 P/E 16.6× · PEG — 15% evidence | 13.8/20 RS sector 5% · RS bench -2.5% · 1Y -13.2%4 of 10 weeks ahead 70% evidence |
| Exact sum: 23.8 + 12.9 + 10.6 + 13.8 = 61.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 56.3/100Thin evidence · provisional56% evidence | TURNING | 21.4/35 Revenue 27% · PAT 37.6% · OPM change 4.3 pp 83% evidence | 14.8/25 ROCE 19.3% · OPM 10.8% 95% evidence | 10.1/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 21.4 + 14.8 + 10.1 + 10 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7UPL LtdUPL | 54.2/100Mixed-positive evidence90% evidence | ASLEEP | 20.6/35 Revenue 11.2% · PAT 100% · OPM change -1 pp 88% evidence | 9.3/25 ROCE 10.1% · OPM 19% 100% evidence | 12.5/20 P/E 28.3× · PEG 0.5 100% evidence | 11.8/20 RS sector 4.9% · RS bench -12.2% · 1Y -16.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 9.3 + 12.5 + 11.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8India Pesticides LtdIPL | 54.0/100Mixed-positive evidence81% evidence | TURNING | 20.0/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.6/25 ROCE 16.7% · OPM 14% 95% evidence | 14.1/20 P/E 16.5× · PEG — 50% evidence | 6.3/20 RS sector -11.9% · RS bench -12.1% · 1Y -27.3%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 13.6 + 14.1 + 6.3 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Jubilant Ingrevia LtdJUBLINGREA | 52.7/100Mixed-positive evidence93% evidence | FADING | 18.2/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.2/25 ROCE 11.4% · OPM 15% 100% evidence | 6.4/20 P/E 36.8× · PEG 2.37 65% evidence | 17.9/20 RS sector 11.8% · RS bench 7.8% · 1Y -5.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 10.2 + 6.4 + 17.9 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Bharat Rasayan LtdBHARATRAS | 51.6/100Mixed-positive evidence77% evidence | ASLEEP | 17.1/35 Revenue 5.8% · PAT 3.5% · OPM change 4 pp 83% evidence | 16.5/25 ROCE 17.4% · OPM 16% 95% evidence | 14.7/20 P/E 13.3× · PEG — 50% evidence | 3.3/20 RS sector -33.2% · RS bench -34.6% · 1Y -51.5%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.1 + 16.5 + 14.7 + 3.3 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Bhagiradha Chemicals & Industries LtdBHAGCHEM | 51.0/100Mixed-positive evidence88% evidence | TURNING | 23.6/35 Revenue 21.7% · PAT 31.1% · OPM change 7.3 pp 65% evidence | 5.8/25 ROCE 4.5% · OPM 12.3% 100% evidence | 2.0/20 P/E 207× · PEG 3.04 100% evidence | 19.6/20 RS sector 22.5% · RS bench 17.9% · 1Y -0.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 5.8 + 2 + 19.6 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12GSP Crop Science LtdGSPCROP | 50.4/100Thin evidence · provisional59% evidence | TURNING | 16.5/35 Revenue 21.2% · PAT 37.8% · OPM change -4 pp 88% evidence | 14.3/25 ROCE 19% · OPM 9% 100% evidence | 9.6/20 P/E 26.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 16.5 + 14.3 + 9.6 + 10 = 50.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Dhanuka Agritech LtdDHANUKA | 46.6/100Mixed-negative evidence96% evidence | ASLEEP | 8.3/35 Revenue 0.9% · PAT -5.3% · OPM change -2.5 pp 88% evidence | 19.1/25 ROCE 28.3% · OPM 22.5% 100% evidence | 13.0/20 P/E 15.6× · PEG 1.72 100% evidence | 6.2/20 RS sector -12.4% · RS bench -16.2% · 1Y -40.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 8.3 + 19.1 + 13 + 6.2 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sumitomo Chemical India Ltdthis pageSUMICHEM | 45.4/100Mixed-negative evidence94% evidence | TURNING | 12.1/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 4.0/20 P/E 44.6× · PEG 4 100% evidence | 10.3/20 RS sector -8.2% · RS bench 6% · 1Y -12.8%9 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 19 + 4 + 10.3 = 45.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 15Rallis India LtdRALLIS | 45.3/100Mixed-negative evidence91% evidence | ASLEEP | 16.1/35 Revenue 7.3% · PAT -28.4% · OPM change 2.6 pp 95% evidence | 9.3/25 ROCE 12.8% · OPM 15.2% 95% evidence | 11.4/20 P/E 26.7× · PEG 0.89 100% evidence | 8.5/20 RS sector -1.8% · RS bench -20.7% · 1Y -39.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.1 + 9.3 + 11.4 + 8.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16NACL Industries LtdNACLIND | 44.9/100Mixed-negative evidence94% evidence | TURNING | 28.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 4.4/25 ROCE 8.1% · OPM 11% 100% evidence | 3.8/20 P/E 171× · PEG 2.02 100% evidence | 8.6/20 RS sector -12.5% · RS bench 3.8% · 1Y -26.9%10 of 10 weeks ahead 70% evidence |
| Exact sum: 28.1 + 4.4 + 3.8 + 8.6 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Astec Lifesciences LtdASTEC | 44.9/100Mixed-negative evidence63% evidence | ASLEEP | 23.3/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 2.6/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.0/20 RS sector -3.5% · RS bench -9.3% · 1Y -27.2%7 of 10 weeks ahead 70% evidence |
| Exact sum: 23.3 + 2.6 + 10 + 9 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Meghmani Organics LtdMOL | 44.3/100Mixed-negative evidence74% evidence | TURNING | 20.6/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 18% 95% evidence | 10.2/20 P/E 21.3× · PEG — 15% evidence | 4.1/20 RS sector -33.7% · RS bench -13.6% · 1Y -42.8%3 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 9.4 + 10.2 + 4.1 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Insecticides India LtdINSECTICID | 43.8/100Mixed-negative evidence77% evidence | ASLEEP | 11.9/35 Revenue 7% · PAT -1.4% · OPM change -2 pp 83% evidence | 13.0/25 ROCE 15.8% · OPM 6% 95% evidence | 11.7/20 P/E 13.5× · PEG — 50% evidence | 7.2/20 RS sector -8.5% · RS bench -9.5% · 1Y -38.7%7 of 10 weeks ahead 70% evidence |
| Exact sum: 11.9 + 13 + 11.7 + 7.2 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Excel Industries LtdEXCELINDUS | 43.1/100Mixed-negative evidence70% evidence | TURNING | 14.4/35 Revenue 12% · PAT -11.8% · OPM change 0 pp 83% evidence | 8.6/25 ROCE 6.1% · OPM 8% 95% evidence | 10.9/20 P/E 16.4× · PEG — 15% evidence | 9.2/20 RS sector -4.6% · RS bench -2.6% · 1Y -27.3%2 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 8.6 + 10.9 + 9.2 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Epigral LtdEPIGRAL | 41.3/100Mixed-negative evidence94% evidence | ASLEEP | 6.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.3/25 ROCE 15.5% · OPM 25% 100% evidence | 16.5/20 P/E 17.3× · PEG 0.43 100% evidence | 4.0/20 RS sector -32.9% · RS bench -17.5% · 1Y -40.9%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.5 + 14.3 + 16.5 + 4 = 41.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22P I Industries LtdPIIND | 40.9/100Mixed-negative evidence90% evidence | ASLEEP | 6.6/35 Revenue -15.9% · PAT -20.5% · OPM change -3 pp 88% evidence | 15.5/25 ROCE 15% · OPM 22% 100% evidence | 10.6/20 P/E 34.7× · PEG 1.71 100% evidence | 8.2/20 RS sector -3.4% · RS bench -15.3% · 1Y -32.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 6.6 + 15.5 + 10.6 + 8.2 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Best Agrolife LtdBESTAGRO | 29.7/100Adverse evidence81% evidence | TURNING | 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.0/25 ROCE 5.2% · OPM 20% 95% evidence | 7.0/20 P/E 22.9× · PEG — 50% evidence | 5.8/20 RS sector -30.7% · RS bench -8.5% · 1Y -36.9%1 of 11 weeks ahead 70% evidence |
| Exact sum: 7.9 + 9 + 7 + 5.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Heranba Industries LtdHERANBA | 25.7/100Adverse evidence65% evidence | ASLEEP | 11.7/35 Revenue 13.1% · PAT -80% · OPM change -2.7 pp 62% evidence | 1.2/25 ROCE -1.6% · OPM -7% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -22% · RS bench -25.7% · 1Y -51.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 1.2 + 10 + 2.8 = 25.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Sumitomo Chemical India Ltd's share price today?
Sumitomo Chemical India Ltd trades at ₹510, −19.1% over the past year. The company is valued at ₹25,471 Cr. The stock sits at 60% of its 52-week range of ₹375–₹602, +8.5% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 3 weeks in. — as of 31 July 2026.
What were Sumitomo Chemical India Ltd's latest quarterly results?
Sumitomo Chemical India Ltd reported revenue of ₹1,063 Cr and net profit of ₹215 Cr for the Jun 26 quarter. Revenue rose 0.6% and profit rose 20.8% year on year. Earnings per share were ₹4.30. The operating margin was 22.0%, 1.0 pp higher than a year earlier. — as of 31 July 2026.
What is Sumitomo Chemical India Ltd's revenue?
Sumitomo Chemical India Ltd reported revenue of ₹1,063 Cr in the Jun 26 quarter, +0.6% year on year. For the full FY26 fiscal year, revenue was ₹3,238 Cr (+2.8%). Over the last 8 years revenue compounded at 6.8% a year. — as of 31 July 2026.
What is Sumitomo Chemical India Ltd's profit?
Sumitomo Chemical India Ltd earned ₹215 Cr of net profit in the Jun 26 quarter, +20.8% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹543 Cr. The operating margin ran 22.0% in the latest quarter. — as of 31 July 2026.
What is Sumitomo Chemical India Ltd's market cap?
Sumitomo Chemical India Ltd's market capitalisation is ₹25,471 Cr at a share price of ₹510. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Sumitomo Chemical India Ltd's P/E ratio?
Sumitomo Chemical India Ltd trades at a P/E of 44.6×, at the 21st percentile of its own 6-year range, against a long-run median of 51.7×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Sumitomo Chemical India Ltd pay a dividend?
Yes — Sumitomo Chemical India Ltd's dividend payout was 12% of profit in FY26, and it recorded a payout in 8 of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Sumitomo Chemical India Ltd overvalued?
On its own history, Sumitomo Chemical India Ltd looks cheap against its own history: its P/E of 44.6× has been cheaper only 21% of the time in 6 years (long-run median 51.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Sumitomo Chemical India Ltd growing?
Yes — Sumitomo Chemical India Ltd is growing: latest-quarter revenue +0.6% year on year, profit +20.8%, and the margin +1.0 pp at 22.0%. The 8-year compound rates are 6.8% (revenue) and 17.9% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Sumitomo Chemical India Ltd performing?
Sumitomo Chemical India Ltd is in a confirmed uptrend, 3 weeks in. Its latest quarter's revenue rose 0.6% and profit rose 20.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Sumitomo Chemical India Ltd in?
Consistent — profit and EPS growth have stayed positive through the window, with ROCE at 22.7% and holding. The read comes from the last 12 quarters of growth (revenue growth −3.6% latest, profit growth +3.9% latest, eps growth +4.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Sumitomo Chemical India Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 3 of stage 2), trading +8.5% versus its 200-day average and at 60% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Sumitomo Chemical India Ltd beating the market?
On recent form, yes — Sumitomo Chemical India Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 6.5 years the stock moved +121% against the NIFTY 500's +136% — behind the index over the full window. — as of 31 July 2026.
Will Sumitomo Chemical India Ltd's share price go up?
This page publishes no price forecast for Sumitomo Chemical India Ltd. What it measures instead: the share price is ₹510, the price is in a confirmed uptrend 3 weeks in. Its P/E of 44.6× sits at the 21st percentile of its own 6-year range. — as of 31 July 2026.
Who owns Sumitomo Chemical India Ltd?
Promoters hold 75.0% of Sumitomo Chemical India Ltd, foreign institutions 3.0%, domestic institutions 9.3% and the public 12.7% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 2.2 points over 8 quarters. — as of 31 July 2026.
Does Sumitomo Chemical India Ltd have too much debt?
No — Sumitomo Chemical India Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill 84×. FY26 borrowings were ₹63.0 Cr against equity of ₹3,390 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Sumitomo Chemical India Ltd's capex?
Sumitomo Chemical India Ltd spent ₹290 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹79.0 Cr, with ₹20.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Sumitomo Chemical India Ltd's cash flow?
Sumitomo Chemical India Ltd generated ₹446 Cr of operating cash flow in FY26 and ₹367 Cr of free cash flow after ₹79.0 Cr of capital spending. Reported profit that year was ₹543 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Sumitomo Chemical India Ltd's profit real cash?
Yes — over the last 3 fiscal years, 117% of Sumitomo Chemical India Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹446 Cr against reported profit of ₹543 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Sumitomo Chemical India Ltd in its business cycle?
Sumitomo Chemical India Ltd's FY26 operating margin was 21.0%, against a 9-year band of 11.0%–21.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 22.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Sumitomo Chemical India Ltd story?
The sharpest disagreement: annual EPS moved +7.4% against a −19.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Sumitomo Chemical India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sumitomo Chemical India Ltd is coiled. The quarters are improving, yet the P/E sits at the 21st percentile of its own 6-year range — the business is moving before the market. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.